[评论] 在高级 gastroenteropancreatic 神经内分泌肿瘤中重新考虑治疗序列VIP

治疗序列在先进的胃肠胃癌神经内分泌肿瘤(GEP-NETs)仍然是一个重大未满足的临床需求.1 虽然索马托斯塔丁受体积极的,差异良好的GEP-NETs往往遵循一些无情的课程,疾病进展最终需要平衡肿瘤控制,毒性,生活质量,和未来治疗的保护的治疗决策

První krok

Treatment sequencing in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) remains a major unmet clinical need.1 Although somatostatin receptor-positive, well differentiated GEP-NETs often follow a somewhat indolent course, disease progression eventually requires treatment decisions that balance tumour control, toxicity, quality of life, and the preservation of future therapeutic options.

Původní zdroj: The Lancet

Trend, který stojí za pozornost